EUVIMEDEUVIMED entdecken
Open Access

Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group

Michael J Satlin, David van Duin, Pranita D Tamma, Thomas P Lodise, Daria Van Tyne, Keith A Rodvold, Nadine Rouphael, Scott R Evans, Vance G Fowler, Toshimitsu Hamasaki, Robin Patel, Lauren Komarow und 6 weitere

Clinical Infectious Diseases · 16.10.2023 · 77 (Supplement_4) · S305-S313

DOI: 10.1093/cid/ciad547 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 16.10.2023. Verfasst von Michael J Satlin und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA. Hauptthemen laut MEDLINE: Fosfomycin, Gram-Negative Bacterial Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FosfomycinGram-Negative Bacterial InfectionsAdultHumansLeadershipAnti-Bacterial AgentsGram-Negative BacteriaCarbapenemsFluoroquinolonesPseudomonas aeruginosaDrug Resistance, Multiple, BacterialMicrobial Sensitivity Tests

Stichwörter der Autor:innen

antimicrobial resistanceclinical trialsgram-negativeinterventional studiesobservational studies

Substanzen

FosfomycinAnti-Bacterial AgentsCarbapenemsFluoroquinolones

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.
  • Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, New York, USA.
  • Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

ORCID-Profile: Yohei Doi

Förderung

  • NIAID NIH HHS
  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • National Institutes of Health

Zitieren

APA

Satlin, M. J., van Duin, D., Tamma, P. D., Lodise, T. P., Van Tyne, D., Rodvold, K. A., Rouphael, N., Evans, S. R., Fowler, V. G., Hamasaki, T., Patel, R., Komarow, L., Baum, K., Souli, M., Schwager, N., Bonomo, R. A., Doi, Y., & Antibacterial Resistance Leadership Group (2023). Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases, 77(Supplement_4), S305-S313. https://doi.org/10.1093/cid/ciad547

Vancouver

Satlin MJ, van Duin D, Tamma PD, Lodise TP, Van Tyne D, Rodvold KA, et al. Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group. Clinical Infectious Diseases. 2023;77(Supplement_4):S305-S313. doi:10.1093/cid/ciad547

BibTeX
@article{Satlin2023,
  author = {Satlin, Michael J and van Duin, David and Tamma, Pranita D and Lodise, Thomas P and Van Tyne, Daria and Rodvold, Keith A and Rouphael, Nadine and Evans, Scott R and Fowler, Vance G and Hamasaki, Toshimitsu and Patel, Robin and Komarow, Lauren and Baum, Keri and Souli, Maria and Schwager, Nyssa and Bonomo, Robert A and Doi, Yohei and Antibacterial Resistance Leadership Group, Antibacterial Resistance Leadership Group},
  title = {Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  volume = {77},
  number = {Supplement_4},
  pages = {S305--S313},
  doi = {10.1093/cid/ciad547}
}
Kostenlos starten →